18 February 2018
News and Views
Links and Services
The most recent issue of the Alimentary Pharmacology & Therapeutics determined the risk of infusion reaction associated with rapid infusions in patients receiving infliximab.
Infliximab is typically administered intravenously via 2- to 3-h duration infusions.
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors